	US 11,707,456 B2
	Processes for preparing arimoclomol citrate and intermediates thereof
Zhe Zhang, Simpsonville, SC (US); Mark Read, Greenville, SC (US); Elisabeth Vang Carstensen, Farum (DK); Marco Poppe, Linz (AT); and Andreas Pelz, Freistadt (AT)
Assigned to KemPharm Denmark A/S
Filed by KemPharm Denmark A/S, Copenhagen (DK)
Filed on Mar. 10, 2022, as Appl. No. 17/691,989.
Application 17/691,989 is a continuation of application No. PCT/EP2021/082294, filed on Nov. 19, 2021.
Claims priority of provisional application 63/211,809, filed on Jun. 17, 2021.
Claims priority of provisional application 63/115,749, filed on Nov. 19, 2020.
Claims priority of application No. 20209467 (EP), filed on Nov. 24, 2020.
Prior Publication US 2022/0273639 A1, Sep. 1, 2022
Int. Cl. A61K 31/4545 (2006.01); A61K 9/20 (2006.01); A61K 9/50 (2006.01)

CPC A61K 31/4545 (2013.01) [A61K 9/2054 (2013.01); A61K 9/5047 (2013.01)]

28 Claims

1. A composition comprising:

a) at least 98.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate;

b) about 1.0% to about 1.9% N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or pharmaceutically acceptable salt thereof; and

c) about 0.05% to about 0.1% methyl (Z)—N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharmaceutically acceptable salt thereof.